| ALIMANDI Maurizio (PI) | LS5 | 18/10/2023-18/10/2025 | € 103.090,00
| BNEWTHERAPY: Combined therapies in a Ptch1+/−/Tis21KO mouse model of medulloblastoma by eliminating cancer cells with anti-ErbB2/4 CAR-T lymphocytes and by a prodifferentiative treatment with chemokine Cxcl3 | Prot. 1110 del 20-07-2023 |
| BELLEUDI Francesca | LS3 | 18/10/2023-18/10/2025 | € 57.000,00 | Deciphering tumor microenvironmental Acidosis and calcium channels/FGFRs network Crosstalk in PDAC for innovative combined Therapy (AdaPtiviTy) | Prot. 971 del 30-06-2023 |
| DE VITIS Claudia | LS3 | 28/09/2023-28/09/2025 | € 66.650,00 | Ovarian cancer cells: from iron addiction to ferroptosis vulnerability | Prot. 971 del 30-06-2023 |
| MENINI Stefano (PI) | LS4 | 18/10/2023-18/10/2025 | € 105.172,00 | Linking glucose metabolic rewiring to glycolysis-derived carbonyl stress in diabetic nephropathy. Revisiting the single unifying hypothesis for diabetic complications. (MeRGe project) | Prot. 1110 del 20-07-2023 |
| MUSUMECI Beatrice | LS4 | 18/10/2023-18/10/2025 | € 59.300,00 | HeArt Rate and quality of Life in transthyrEtin cardiac amYloidosis (HARLEY) | Prot. 1110 del 20-07-2023 |
| RUBATTU Donatella Speranza | LS1 | 7/10/2023-7/10/2025 | € 60.000,00 | Dissecting a molecular mechanism for cardiac hypertrophy in hypertension: roles of mitochondrial NDUFC2-dependent Complex I dysfunction and of mitochondrial permeability transition | Prot. 1017 del 7-07-2023 |
| SESTI Giorgio | LS4 | 18/10/2023-18/10/2025 | € 50.201,00 | Effects of glucagon on hepatic expression of inflammatory markers | Prot. 1110 del 20-07-2023 |
| STIGLIANO Antonio | LS4 | 18/10/2023-18/10/2025 | € 67.738,00 | Multiparametric characterization of adreno-cortical tumors (radiomic, immune and proteomic profiles) and association with extra-adrenal neoplasms (IMPROVE STUDY) | Prot. 1065 del 18-07-2023 |
